
The Copenhagen-based biotech company IO Biotech will not be deterred by the fact that a number of US giants have dropped clinical studies with the enzyme IDO, which IO Biotech's main asset deals with.
Both Merck/MSD, Bristol-Meyers Squibb, AstraZeneca and Roche have dropped IDO programs after the US biotech company Incyte failed a phase 3 study in April.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app